CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

PATIENT ID : VINAM131069181

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 21/04/2023 08:02:29 REPORTED: 25/04/2023 11:40:52

CLINICAL INFORMATION:

STOOL CANCEL

Biological Reference Interval Test Report Status Results Units **Final**

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

XRAY-CHEST

MILD UNFOLDING OF AORTA WITH AORTIC KNUCKLE CALCIFICATION **IMPRESSION**

NOTED. (AGE RELATED)

TMT OR ECHO

NEGATIVE TMT OR ECHO

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

HYPERTENSIVE SINCE 14 YEARS BACK. RELEVANT PRESENT HISTORY

DYSLIPIDEMIA ON TREATMENT.

RELEVANT PAST HISTORY COVID IN 2021. HOME QUATANTINTED.

RELEVANT PERSONAL HISTORY MARRIED / VEG. DIET / NO ALLERGIES / NO SMOKING / NO ALCOHOL.

30TH PARENTES: - HIGH BLOOD PRESSURE RELEVANT FAMILY HISTORY

TAB: - STAMLO T / ROZAVEL F HISTORY OF MEDICATIONS

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.67 mts WEIGHT IN KGS. 91 Kgs

BMI 33

BMI & Weight Status as follows/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

NORMAL MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE OBESE GENERAL APPEARANCE / NUTRITIONAL

STATUS **BUILT / SKELETAL FRAMEWORK AVERAGE** FACIAL APPEARANCE NORMAL NORMAL SKIN **UPPER LIMB** NORMAL NORMAL LOWER LIMB

Page 1 Of 18



PERFORMED AT:

SRLLtd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: customercare.thane@srl.in



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

PATIENT ID : VINAM131069181

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 21/04/2023 08:02:29 REPORTED: 25/04/2023 11:40:52

CLINICAL INFORMATION:

STOOL CANCEL

Biological Reference Interval Test Report Status Results Units **Final**

NORMAL NECK

NOT ENLARGED OR TENDER NECK LYMPHATICS / SALIVARY GLANDS

NOT ENLARGED THYROID GLAND NORMAL CAROTID PULSATION **TEMPERATURE** NORMAL

84/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID **PULSE**

3RUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

ВР mm/Hg 130/80 MM HG

(SUPINE)

PERICARDIUM NORMAL NORMAL APEX BEAT NORMAL **HEART SOUNDS** ABSENT MURMURS

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL MOVEMENTS OF CHEST SYMMETRICAL **BREATH SOUNDS INTENSITY** NORMAL

VESICULAR (NORMAL) **BREATH SOUNDS QUALITY**

ADDED SOUNDS ABSENT

PER ABDOMEN

NORMAL APPEARANCE ABSENT VENOUS PROMINENCE NOT PALPABLE LIVER **SPLEEN** NOT PALPABLE ABSENT **HERNIA**

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CEREBELLAR FUNCTIONS NORMAL

Page 2 Of 18





PERFORMED AT:

MAHARASHTRA, INDIA

SRLLtd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VINAM131069181 DRAWN

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: DELHÍ

RECEIVED: 21/04/2023 08:02:29 ABHA NO REPORTED: 25/04/2023 11:40:52 NEW DELHI 110030

CLINICAL INFORMATION:

STOOL CANCEL

8800465156

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
SENSORY SYSTEM	VORMAL	
MOTOR SYSTEM	VORMAL	
REFLEXES	VORMAL	
MUSCULOSKELETAL SYSTEM		
SPINE	VORMAL	
JOINTS	VORMAL	
BASIC EYE EXAMINATION		
CONJUNCTIVA	VORMAL	
EYELIDS	VORMAL	
EYE MOVEMENTS	VORMAL	
CORNEA	NORMAL	
DISTANT VISION RIGHT EYE WITHOUT	REDUCED VISUAL ACU:	ПҮ 6/36
GLASSES	ANTTE ITNENDOMAN ELTMIT	-
DISTANT VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT	
DISTANT VISION RIGHT EYE WITH GLASSES	WITH GLASSES NORMA	AL .
DISTANT VISION LEFT EYE WITH GLASSES	WITH GLASSES NORMA	AL .
NEAR VISION RIGHT EYE WITHOUT GLASSES	REDUCED VISUAL ACU	TYN/36
NEAR VISION LEFT EYE WITHOUT GLASSES	REDUCED VISUAL ACU:	TYN/36
NEAR VISION RIGHT EYE WITH GLASSES	WITHIN NORMAL LIMIT	Ţ
NEAR VISION LEFT EYE WITH GLASSES	WITHIN NORMAL LIMIT	Ţ
COLOUR VISION	VORMAL	
BASIC DENTAL EXAMINATION		
TEETH	CARIES	
SUMMARY		
RELEVANT HISTORY	NOT SIGNIFICANT	
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT	

Page 3 Of 18





SRLLtd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) : VINAM131069181 PATIENT ID DRAWN

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 21/04/2023 08:02:29 DELHÍ ABHA NO REPORTED: 25/04/2023 11:40:52 NEW DELHI 110030

CLINICAL INFORMATION:

STOOL CANCEL

8800465156

Biological Reference Interval Units Test Report Status Results **Final**

FOLLOW UP WITH PHYSICIANS FOR BLOOD PRESSURE CONTROL. REMARKS / RECOMMENDATIONS

DENTAL CONSULT FOR TREATMENT OF DENTAL CARIES. WEIGHT LOSS:-LOW CALORIE, HIGH FIBRE DIET, REGULAR EXERCISE.

REGULAR EXERCISE REGULAR WALK FOR 30-40 MIN DAILY. REPEAT LIPID PROFILE, BLOOD SUGAR AFTER 3 MONTHS OF DIET AND

EXERCISE.

DRINK 3-4 LIT WATER DAILY.

UROLOGY CONSULT FOR RENALCALCULI.

Page 4 Of 18







SRLLtd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

PATIENT ID : VINAM131069181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 21/04/2023 08:02:29 DELHÍ ABHA NO REPORTED: 25/04/2023 11:40:52 NEW DELHI 110030

CLINICAL INFORMATION:

STOOL CANCEL

8800465156

Biological Reference Interval Test Report Status Results Units **Final**

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN GRADE I FATTY LIVER.

BILATERAL RENAL NON-OBSTRUCTING CALCULI.

Interpretation(s)

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Page 5 Of 18







SRLLtd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years

Male ACROFEMI HEALTHCARE LTD (MEDIWHEEL) : VINAM131069181

PATIENT ID F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: DELHÍ

ABHA NO NEW DELHI 110030

DRAWN

RECEIVED: 21/04/2023 08:02:29 REPORTED: 25/04/2023 11:40:52

CLINICAL INFORMATION:

STOOL CANCEL

8800465156

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units

HAEMATOLOGY - CBC						
MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE						
BLOOD COUNTS, EDTA WHOLE BLOOD						
HEMOGLOBIN (HB)	14.4	13.0 - 17.0	g/dL			
METHOD: SLS-HEMOGLOBIN DETECTION METHOD RED BLOOD CELL (RBC) COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION	4.94	4.5 - 5.5	mil/µL			
WHITE BLOOD CELL (WBC) COUNT METHOD: FLUORESCENCE FLOW CYTOMETRY	8.22	4.0 - 10.0	thou/µL			
PLATELET COUNT	343	150 - 410	thou/µL			
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION RBC AND PLATELET INDICES						
HEMATOCRIT (PCV) METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD	43.6	40.0 - 50.0	%			
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED FROM RBC & HCT	88.3	83.0 - 101.0	fL			
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED FROM THE RBC & HGB	29.1	27.0 - 32.0	pg			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED FROM THE HGB & HCT	33.0	31.5 - 34.5	g/dL			
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE	12.8	11.6 - 14.0	%			
MENTZER INDEX	17.9					
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMA	9.6	6.8 - 10.9	fL			
WBC DIFFERENTIAL COUNT	TOGAT					
NEUTROPHILS METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	51	40 - 80	%			
LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	38	20 - 40	%			
MONOCYTES	9	2 - 10	%			
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING EOSINOPHILS	2	1 - 6	%			
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT	4.19	2.0 - 7.0	thou/µL			

Dr.(Mrs)Neelu K Bhojani Lab Head

PERFORMED AT:





Page 6 Of 18





Fax : CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years

Male ACROFEMI HEALTHCARE LTD (MEDIWHEEL) DRAWN

PATIENT ID : VINAM131069181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: DELHÍ

RECEIVED: 21/04/2023 08:02:29 ABHA NO REPORTED: 25/04/2023 11:40:52 NEW DELHI 110030 8800465156

CLINICAL INFORMATION:

STOOL CANCEL

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	0.40.11.1		
ABSOLUTE LYMPHOCYTE COUNT	3.13 High	1.0 - 3.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE MONOCYTE COUNT	0.70	0.2 - 1.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE EOSINOPHIL COUNT	0.17	0.02 - 0.50	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.3		
MORPHOLOGY			
RBC	NORMOCYTIC NORM	1OCHROMIC	
WBC	NORMAL MORPHOLO	DGY	
METHOD: MICROSCOPIC EXAMINATION			
PLATELETS	ADEQUATE		

Interpretation(s)

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(> 13)

from Beta thal assaemi a trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the golc standard for

diagnosing a case of bets thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age — 49.5 years old and NLR — 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR — 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR — 3.4, 46.1% COVID-19 patients with mild disease might become severe. 3.3, COVID-19 patients tend to show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 7 Of 18





CODE/NAME & ADDRESS : C000138394

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

REF. DOCTOR: SELF ACCESSION NO: 0181WD000978

PATIENT ID : VINAM131069181

CLIENT PATIENT ID:

ABHA NO

AGE/SEX :53 Years

DRAWN

RECEIVED: 21/04/2023 08:02:29

Male

REPORTED: 25/04/2023 11:40:52

CLINICAL INFORMATION:

STOOL CANCEL

Biological Reference Interval Test Report Status Results Units <u>Final</u>

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

mm at 1 hr E.S.R 6 < 15

METHOD: MODIFIED WESTERGREN

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays' fully automated instruments are available to measure ESR

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Intections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as 'bacterial endocarditis').
In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increasec fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haem atology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haem atology by Dadie and Lewis, 10th edition.

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 8 Of 18



CODE/NAME & ADDRESS : C000138394

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

ACCESSION NO: 0181WD000978

PATIENT ID : VINAM131069181

REF. DOCTOR: SELF

CLIENT PATIENT ID:

ABHA NO

AGE/SEX :53 Years

DRAWN

RECEIVED: 21/04/2023 08:02:29 REPORTED: 25/04/2023 11:40:52

Male

CLINICAL INFORMATION:

STOOL CANCEL

Biological Reference Interval Test Report Status Results Units **Final**

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: GEL COLUMN AGGLUTINATION METHOD.

RH TYPE **POSITIVE**

METHOD: GEL COLUMN AGGLUTINATION METHOD.

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant womer are not available, please check with the patient records for

The test is performed by both forward as well as reverse grouping methods.

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 9 Of 18



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030 8800465156

: VINAM131069181

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 21/04/2023 08:02:29 REPORTED: 25/04/2023 11:40:52

CLINICAL INFORMATION:

STOOL CANCEL

Biological Reference Interval Test Report Status Results Units **Final**

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

HBA1C Non-diabetic Adult < 5.7 5.7

Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0

Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HPLC

116.9 High mg/dL ESTIMATED AVERAGE GLUCOSE(EAG) < 116.0

METHOD: CALCULATED PARAMETER

GLUCOSE FASTING, FLUORIDE PLASMA

Normal 75 - 99 mg/dL FBS (FASTING BLOOD SUGAR) 94

> Pre-diabetics: 100 - 125 Diabetic: > or = 126

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 67 Low 70 - 139 mg/dL

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE

LIPID PROFILE, SERUM

180 Desirable: < 200 ma/dL CHOLESTEROL, TOTAL

Borderline: 200 - 239 High: > / = 240

METHOD: ENZYMATIC COLORIMETRIC ASSAY

Normal: < 150 mg/dL TRIGLYCERIDES 111

Borderline high: 150 - 199

High: 200 - 499 Very High: >/= 500

METHOD: ENZYMATIC COLORIMETRIC ASSAY

48 At Risk: < 40 mg/dL HDL CHOLESTEROL

Desirable: > or = 60METHOD: ENZYMATIC, COLORIMETRIC

Dr. Ushma Wartikar Consultant Pathologist

Dr.Priyal Chinchkhede Consultant Pathologist

Bhindhehede

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 10 Of 18



SRLLtd Mulund Goregoan Link Roac MUMBAI, 400078 MAHARASHTRA, INDIA CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

: VINAM131069181

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 21/04/2023 08:02:29 REPORTED: 25/04/2023 11:40:52

CLINICAL INFORMATION:

STOOL CANCEL

Test Report Status Final	Results	Biological Reference Interval	l Units
CHOLESTEROL LDL	110 High	Adult levels: Optimal < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY NON HDL CHOLESTEROL	132 High	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	22.2	< OR = 30.0	mg/dL
CHOL/HDL RATIO	3.8	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
LDL/HDL RATIO	2.3	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderat Risk >6.0 High Risk	
Interpretation(s)		J	
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD: COLORIMETRIC DIAZO	0.41	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.24	< 0.30	mg/dL
BILIRUBIN, INDIRECT	0.17	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: COLORIMETRIC	7.2	6.0 - 8.0	g/dL
ALBUMIN METHOD: COLORIMETRIC	4.6	3.97 - 4.94	g/dL
GLOBULIN	2.6	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.8	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	17	< OR = 50	U/L

Dr. Ushma Wartikar Consultant Pathologist

PERFORMED AT:

Bhinchkhede.

Dr.Priyal Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 11 Of 18



CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS : C000138394

ACCESSION NO: 0181WD000978 AGE/SEX :53 Years Male ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

DRAWN

RECEIVED: 21/04/2023 08:02:29

REPORTED: 25/04/2023 11:40:52

PATIENT ID : VINAM131069181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: DELHI

ABHA NO NEW DELHI 110030

CLINICAL INFORMATION:

STOOL CANCEL

8800465156

Test Report Status <u>Final</u>	Results	Biological Reference Int	erval Units
METHOD: UV ABSORBANCE ALANINE AMINOTRANSFERASE (ALT/SGPT)	22	< OR = 50	U/L
METHOD: UV ABSORBANCE			,
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	88	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	16	0 - 60	U/L
LACTATE DEHYDROGENASE METHOD: UV ABSORBANCE BLOOD UREA NITROGEN (BUN), SERUM	182	125 - 220	U/L
BLOOD UREA NITROGEN METHOD: ENZYMATIC ASSAY CREATININE, SERUM	9	6 - 20	mg/dL
CREATININE METHOD: COLORIMETRIC BUN/CREAT RATIO	0.92	0.7 - 1.2	mg/dL
BUN/CREAT RATIO URIC ACID, SERUM	9.78	8.0 - 15.0	
URIC ACID METHOD: ENZYMATIC COLORIMETRIC ASSAY TOTAL PROTEIN, SERUM	5.0	3.4 - 7.0	mg/dL
TOTAL PROTEIN METHOD: COLORIMETRIC ALBUMIN, SERUM	7.2	6.0 - 8.0	g/dL
ALBUMIN METHOD: COLORIMETRIC GLOBULIN	4.6	3.97 - 4.94	g/dL
GLOBULIN	2.6	2.0 - 3.5	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	140	136 - 145	mmol/L
POTASSIUM, SERUM	4.62	3.5 - 5.1	mmol/L
CHLORIDE, SERUM	104	98 - 107	mmol/L
Interpretation(s)			
Sodium Potassium	(Chloride	

Dr. Ushma Wartikar Consultant Pathologist

PERFORMED AT:

Bhindhehede.

Dr.Priyal Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head








Page 12 Of 18



CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years

Male ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

PATIENT ID : VINAM131069181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 21/04/2023 08:02:29 DELHI ABHA NO REPORTED: 25/04/2023 11:40:52 NEW DELHI 110030

CLINICAL INFORMATION:

STOOL CANCEL

8800465156

Biological Reference Interval Test Report Status Results Units **Final**

Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrolic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, antidepressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmolic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.	
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea), diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic lamilial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, MSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim sulfamethoxazole.	Increased in: Renal lailure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.	
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLI counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)	

Interpretation(s)

GLYCÓSYLATED HÉMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- Evaluating the long-term control of blood glucose concentrations in diabetic patients.
 Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

- The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

- **HbA1c Estimation can get affected due to :**1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g., recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test résults. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

- a) Homozygous hemoglobinopathy. Fructosamıne is recommended for testing of HbA1c.
 b) Heterozygous state detected (010 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

Dr. Ushma Wartikar Consultant Pathologist



Dr.Priyal Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 13 Of 18





SRLLtd Mulund Goregoan Link Roac MUMBAI, 400078 MAHARASHTRA, INDIA CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000978 :53 Years AGE/SEX

Male ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID DRAWN

: VINAM131069181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

LIENT PATIENT ID: RECEIVED: 21/04/2023 08:02:29 DELHI ABHA NO REPORTED: 25/04/2023 11:40:52 NEW DELHI 110030

CLINICAL INFORMATION:

STOOL CANCEL

8800465156

Biological Reference Interval Units Results Test Report Status <u>Final</u>

recommended for detecting a hemoglobinopathy
GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**Normally, the glucose concentration in extracellular fluic is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides. Decreased in: Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insulficiency, hypopituitarism, diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol; sulfonylureas,tolbutamide,anc other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycsuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish prigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropiolesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin in bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated indirect) bilirubin is also elevated indirect. attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and rec blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many basues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dystunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive

liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerul onephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein, Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular

permeability or decreased lymphatic clearance, mainutrition and wasting etc.

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blooc flow, Loss of body fluic (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blooc pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Scierosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of proteir in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Ushma Wartikar Consultant Pathologist Dr.Priyal Chinchkhede Consultant Pathologist

Dhindrehede.

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 14 Of 18

View Report



CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000978 AGE/SEX :53 Years Male

ABHA NO

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

DRAWN : VINAM131069181

CLIENT PATIENT ID:

RECEIVED: 21/04/2023 08:02:29

REPORTED: 25/04/2023 11:40:52

CLINICAL INFORMATION:

STOOL CANCEL

Biological Reference Interval Test Report Status Results Units **Final**

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

PΗ 6.0 5.00 - 7.50 SPECIFIC GRAVITY 1.020 1.010 - 1.030

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

PROTEIN NOT DETECTED NOT DETECTED **GLUCOSE** DETECTED (++) NOT DETECTED KETONES NOT DETECTED NOT DETECTED BLOOD NOT DETECTED NOT DETECTED

UROBILINOGEN NORMAL NORMAL

NITRITE NOT DETECTED NOT DETECTED LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF /HPF PUS CELL (WBC'S) 2-3 0-5 0-5 /HPF **EPITHELIAL CELLS** 1-2

CASTS NOT DETECTED NOT DETECTED **CRYSTALS**

BACTERIA NOT DETECTED NOT DETECTED YEAST NOT DETECTED NOT DETECTED

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

REMARKS PRESENCE OF URINARY GLUCOSE RECHECKED BY MANUAL METHOD.

Interpretation(s)

Bhindrehede Dr.Priyal Chinchkhede

Consultant Pathologist


Dr. Ushma Wartikar Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 15 Of 18



Mulund Goregoan Link Roac MUMBAI, 400078 MAHARASHTRA, INDIA

CIN - U74899PB1995PLC045956



CODE/NAME & ADDRESS : C000138394

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

REF. DOCTOR: SELF ACCESSION NO: 0181WD000978

: VINAM131069181 PATIENT ID

CLIENT PATIENT ID:

ABHA NO

AGE/SEX :53 Years

DRAWN

RECEIVED: 21/04/2023 08:02:29

Male

REPORTED: 25/04/2023 11:40:52

CLINICAL INFORMATION:

STOOL CANCEL

Test Report Status **Final** Results

Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

MICROSCOPIC EXAMINATION, STOOL

REMARK

SAMPLE NOT RECEIVED

Interpretation(s)

Dr. Sheetal Sawant Consultant Microbiologist

Page 16 Of 18



PERFORMED AT:

SRLLtd Mulund Goregoan Link Roac MUMBAI, 400078 MAHARÁSHTRA, INDIA CIN - U74899PB1995PLC045956

CODE/NAME & ADDRESS : C000138394

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

REF. DOCTOR: SELF ACCESSION NO: 0181WD000978

PATIENT ID : VINAM131069181

CLIENT PATIENT ID:

ABHA NO

AGE/SEX :53 Years

DRAWN

RECEIVED: 21/04/2023 08:02:29

REPORTED: 25/04/2023 11:40:52

Male

CLINICAL INFORMATION:

STOOL CANCEL

Biological Reference Interval Test Report Status Results Units **Final**

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

THYROID PANEL, SERUM

110.0 80 - 200 ng/dL

METHOD: ELECTROCHEMILUMINESCENCE

T4 6.46 5.1 - 14.1 µg/dL METHOD: ELECTROCHEMILUMINESCENCE

0.27 - 4.2TSH (ULTRASENSITIVE) 4.120 μIU/mL

METHOD: ELECTROCHEMILUMINESCENCE

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSII.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSII levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSII levels are low. owidetlparowidetlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSII & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor

Dr. Ushma Wartikar Consultant Pathologist Bhindhehede

Dr.Priyal Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 17 Of 18



CODE/NAME & ADDRESS : C000138394 ACCESSION NO : 0181WD000978 AGE/SEX : 53 Years Male

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : VINAM131069181 DRAWN :

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLINICAL INFORMATION:

STOOL CANCEL

Test Report Status <u>Final</u> Results Biological Reference Interval Units

7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hypothyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4. TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Ushma Wartikar Consultant Pathologist

Dr.Priyal Chinchkhede Consultant Pathologist

Bhinchkhede.

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 18 Of 18

View Details

View Report

